Mesoblast Limited

Announcements / Press Releases

2017-February-27	Mesoblast Presents Corporate Update and Financial Results for the Half Year Period Ended December 31, 2016 (in PDF)
2017-February-16	Durable Responses and Sustained Low Disease Activity Over Nine Months After a Single Dose of Mesoblast Cell Therapy in Rheumatoid Arthritis Patients Resistant to Anti-TNF Agents (in PDF)
2017-February-13	Published Study Results Show that Mesoblast Cells Administered Intravenously Significantly Ameliorate Joint Disease in Model of Early Rheumatoid Arthritis (in PDF)
2017-February-10	Release of Shares from Voluntary Escrow (in PDF)
2017-January-31	Appendix 4C - Quarterly Report for Entities Subject to Listing Rule 4.7B (in PDF)
2017-January-31	Mesoblast Director Recognized by Peers for Cardiovascular Leadership (in PDF)
2017-January-11	Mesoblast to Present at 35th Annual J.P. Morgan Healthcare Conference (in PDF)
2017-January-9	Appendix 3B - New Issue Announcement, Application for Quotation of Additional Securities and Agreement (in PDF)
2017-January-9	Mesoblast Receives A$29.6 Million Following Share Issue to Mallinckrodt (in PDF)
2016	2016 Announcements / Press Releases
2015	2015 Announcements / Press Releases
2014	2014 Announcements / Press Releases
2013	2013 Announcements / Press Releases
2012	2012 Announcements / Press Releases
2011	2011 Announcements / Press Releases
2010	2010 Announcements / Press Releases
2009	2009 Announcements / Press Releases
2008	2008 Announcements / Press Releases
2007	2007 Announcements / Press Releases